Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Synairgen provides update on progress during 2023
MP3•Episode home
Manage episode 425897476 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Synairgen PLC chief executive Richard Marsden takes Proactive's Stephen Gunnion through the company's progress and future plans following the release of its full-year results. Marsden provided an overview of Synairgen's work over the past year, focusing on the development of an inhaled, broad-spectrum antiviral drug aimed at treating common respiratory viruses. He highlighted the exciting data generated from various clinical trials during the COVID-19 pandemic. Despite a decrease in hospitalisations due to current virus strains, the trials showed promising results in preventing severe outcomes in infected patients. Synairgen is now focusing on a Phase II trial for mechanically ventilated patients with severe viral lung infections. Marsden explained the rationale behind targeting this population, noting the high mortality rates and lack of antiviral therapeutic options for these patients. He also discussed the company's preparations for the trial, including lab work and collaborations with intensive care physicians. Marsden emphasised the strong commercial case for developing effective treatments in this area. Looking ahead, Synairgen is exploring funding options to support the upcoming trial, set to commence this winter. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Synairgen #ClinicalTrials #RichardMarsden #AntiviralDrug #RespiratoryViruses #Phase2Trial #COVID19 #MedicalResearch #HealthcareInnovation #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodes
MP3•Episode home
Manage episode 425897476 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Synairgen PLC chief executive Richard Marsden takes Proactive's Stephen Gunnion through the company's progress and future plans following the release of its full-year results. Marsden provided an overview of Synairgen's work over the past year, focusing on the development of an inhaled, broad-spectrum antiviral drug aimed at treating common respiratory viruses. He highlighted the exciting data generated from various clinical trials during the COVID-19 pandemic. Despite a decrease in hospitalisations due to current virus strains, the trials showed promising results in preventing severe outcomes in infected patients. Synairgen is now focusing on a Phase II trial for mechanically ventilated patients with severe viral lung infections. Marsden explained the rationale behind targeting this population, noting the high mortality rates and lack of antiviral therapeutic options for these patients. He also discussed the company's preparations for the trial, including lab work and collaborations with intensive care physicians. Marsden emphasised the strong commercial case for developing effective treatments in this area. Looking ahead, Synairgen is exploring funding options to support the upcoming trial, set to commence this winter. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Synairgen #ClinicalTrials #RichardMarsden #AntiviralDrug #RespiratoryViruses #Phase2Trial #COVID19 #MedicalResearch #HealthcareInnovation #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.